PharmaCyte Biotech, Inc. — Form 10-Q Summary
Period clarification: The filing covers the three and nine months ended January 31, 2020, corresponding to the company’s fiscal 2020 third quarter—not calendar 2019 Q3. Financial statements are unaudited.
Business context
PharmaCyte is a pre-revenue biotechnology company developing cellular therapies based on its Cell-in-a-Box encapsulation technology. Its principal near-term program is a proposed LAPC clinical trial using encapsulated cells and ifosfamide. The company says it is preparing an FDA investigational new drug (IND) submission; other cancer and diabetes programs are on hold for further company-funded development until that submission.
Financial results and liquidity
| Metric | Three months ended Jan. 31 | Nine months ended Jan. 31 |
|---|---|---|
| Revenue, 2020 and 2019 | $0 in both periods | $0 in both periods |
| Operating expenses, 2020 | $875,308 | $3,076,505 |
| Net loss, 2020 | $875,308 | $3,076,505 |
| Net loss, 2019 | $676,347 | $2,928,284 |
| Operating cash used, 2020 / 2019 | Not presented | $1,698,981 / $2,216,549 |
| Financing cash provided, 2020 / 2019 | Not presented | $1,333,500 / $1,860,000 |
At January 31, 2020, cash was $142,242, current assets $209,194, current liabilities $1,018,854, total assets $5,338,186, and stockholders’ equity $4,319,332. Working capital was approximately negative $810,000. The balance sheet reports no debt; liabilities shown are accounts payable and accrued expenses. Gross and operating margins are not meaningful because the company had no revenue.
Changes versus prior comparable periods
- Third-quarter operating expenses rose $198,961 (about 29%) year over year, and quarterly net loss increased by the same amount. R&D, director fees, compensation, legal and professional costs, and general and administrative costs all increased.
- Nine-month operating expenses rose $148,221 (about 5%); net loss increased from $2,928,284 to $3,076,505. Higher director, legal/professional, general and administrative, and compensation expenses more than offset a $238,473 reduction in R&D spending.
- Cash used in operations decreased to $1,698,981 from $2,216,549, while financing proceeds fell to $1,333,500 from $1,860,000. Cash declined $373,011 during the nine months to $142,242.
- Common shares outstanding increased from 1,186,004,505 at April 30, 2019 to 1,428,471,172 at January 31, 2020. The filing reports 1,481,471,172 shares outstanding as of March 13, 2020.
Outlook, risks and notable items
- Management states that substantial additional capital is required, expects continued operating losses, and says these conditions raise substantial doubt about the company’s ability to continue as a going concern.
- The company needs further funding to complete the LAPC IND preparation. Planned IND-related service agreements are estimated to cost approximately $220,000, including $40,000 for related parties. The filing gives no firm IND submission date or clinical-trial start guidance, and FDA acceptance or approval is uncertain.
- Management regained eligibility to use its Form S-3 in late January 2020 and planned to continue registered share sales until filing its fiscal 2020 Form 10-K, when it believed S-3 use would no longer be available. Subsequent to quarter-end, it reported $65,000 raised in a private placement and approximately $186,000 net from S-3 block trades through March 13.
- Disclosure controls and internal controls over financial reporting were deemed ineffective due to material weaknesses involving contract preparation and review, inadequate segregation of CFO duties, and IT controls and documentation. Management said remediation work was underway; the weaknesses create risk of financial misstatement or restatement.
- Equity compensation and stock issuance were significant. During the nine months, the company reported net proceeds of approximately $884,000 from S-3 block trades and $450,000 from a private placement; share-based compensation and stock issued for services also contributed to expenses.
- License terms include royalties on future sales and sublicense receipts; the Melligen diabetes license also includes potential milestone payments. The company reported no material pending legal proceedings.
Key facts investors should verify
- Whether subsequent financing is sufficient to fund operations and complete the LAPC IND, and the company’s actual cash runway.
- IND completion and FDA submission status, remaining regulatory/manufacturing work, and any resulting clinical-trial timeline.
- Progress in remediating the disclosed control weaknesses and whether later filings identify effective controls.
- Updated shares outstanding, financing terms, and potential dilution from options, warrants, and further equity offerings.
- Whether planned program spending, including paused non-LAPC programs, and material related-party arrangements change.